Products

Clindamycin has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as Streptococci, Staphylococci and Pneumococci: upper respiratory tract infections, lower respiratory tract infections, skin and soft tissue infections, bone and joint infections, pelvic infections, intra-abdominal infections, septicemia and endocarditis, dental infections. As an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant Plasmodium falciporum infection.

Adults Serious Infections: 150 mg - 300 mg every six hours. More severe infections: 300 mg - 450 mg every six hours. Pediatric Patients Serious Infections: 8 - 16 mg/kg/day divided into three or four equal doses. More severe infections: 16 - 20 mg/kg/day divided into three or four equal doses.

Clindamycin is contraindicated in patients previously found to be sensitive to Clindamycin or lincomycin or any of the ingredients of this medicine.